Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:1378-1387
Published online before print March 3, 2008, doi: 10.1161/CIRCULATIONAHA.107.752618
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/11/1378    most recent
CIRCULATIONAHA.107.752618v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by DeGeorge, B. R.
Right arrow Articles by Koch, W. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeGeorge, B. R., Jr
Right arrow Articles by Koch, W. J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Apoptosis
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies
Right arrowRelated Article

(Circulation. 2008;117:1378-1387.)
© 2008 American Heart Association, Inc.


Heart Failure

Targeted Inhibition of Cardiomyocyte Gi Signaling Enhances Susceptibility to Apoptotic Cell Death in Response to Ischemic Stress

Brent R. DeGeorge, Jr, BS; Erhe Gao, MD, PhD; Matthieu Boucher, PhD; Leif E. Vinge, MD, PhD; Jeffrey S. Martini, BS; Philip W. Raake, MD; J. Kurt Chuprun, PhD; David M. Harris, PhD; Gilbert W. Kim, BS; Stephen Soltys, BS; Andrea D. Eckhart, PhD; Walter J. Koch, PhD

From the Center for Translational Medicine (B.R.D., E.G., M.B., L.E.V., J.S.M., P.W.R., J.K.C., D.M.H., G.W.K., S.S., A.D.E., W.J.K.), George Zallie and Family Laboratory of Cardiovascular Gene Therapy (B.R.D., E.G., M.B., L.E.V., J.S.M., P.W.R., J.K.C., G.W.K., S.S., W.J.K.), and Eugene Feiner Laboratory of Vascular Biology and Thrombosis (D.M.H., A.D.E.), Thomas Jefferson University, Philadelphia, Pa, and Institute for Surgical Research, University of Oslo, Oslo, Norway (L.E.V.).

Correspondence to Walter J. Koch, PhD, FAHA, W.W. Smith Professor of Medicine and Director, Center for Translational Medicine and George Zallie and Family Laboratory of Cardiovascular Gene Therapy, Thomas Jefferson University, 1025 Walnut St, Room 317, Philadelphia, PA 19107. E-mail walter.koch{at}jefferson.edu

Received November 14, 2007; accepted January 22, 2008.

Background— A salient characteristic of dysfunctional myocardium progressing to heart failure is an upregulation of the adenylyl cyclase inhibitory guanine nucleotide (G) protein {alpha} subunit, G{alpha}i2. It has not been determined conclusively whether increased Gi activity in the heart is beneficial or deleterious in vivo. Gi signaling has been implicated in the mechanism of cardioprotective agents; however, no in vivo evidence exists that any of the G{alpha} subunits are cardioprotective. We have created a novel molecular tool to specifically address the role of Gi proteins in normal and dysfunctional myocardium.

Methods and Results— We have developed a class-specific Gi inhibitor peptide, GiCT, composed of the region of G{alpha}i2 that interacts specifically with G protein–coupled receptors. GiCT inhibits Gi signals specifically in vitro and in vivo, whereas Gs and Gq signals are not affected. In vivo expression of GiCT in transgenic mice effectively causes a "functional knockout" of cardiac G{alpha}i2 signaling. Inducible, cardiac-specific GiCT transgenic mice display a baseline phenotype consistent with nontransgenic mice. However, when subjected to ischemia/reperfusion injury, GiCT transgenic mice demonstrate a significant increase in infarct size compared with nontransgenic mice (from 36.9±2.5% to 50.9±4.3%). Mechanistically, this post-ischemia/reperfusion phenotype includes increased myocardial apoptosis and resultant decreased contractile performance.

Conclusions— Overall, our results demonstrate the in vivo utility of GiCT to dissect specific mechanisms attributed to Gi signaling in stressed myocardium. Our results with GiCT indicate that upregulation of G{alpha}i2 is an adaptive protective response after ischemia to shield myocytes from apoptosis.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 1353. [Full Text]